申请人:JIANGSU SIMCERE PHARMACEUTICAL R&D Co., Ltd
公开号:US20140011856A1
公开(公告)日:2014-01-09
Provided are acid addition salts of (Z)—N-[2-(diethylamino)ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-indol-3-ylidene)-4,5,6,7-tetrahydro-1H-indol-3-carboxamide, wherein the salt comprising at least one of a number of salts including L-malate, hydrochloride, phosphate, L-tartrate, benzenesulfonate, sulfate, methanesulfonate, succinate, citrate, fumarate, p-toluenesulfonate, hydrobromate, L-mandelate, lactate, acetate or maleate salt. Also provided is a pharmaceutical composition comprising the salt compounds, and a method of treatment by administering a therapeutically effective amount of the salt compounds as preparation of medicaments.
提供的是(Z)-N-[2-(
二乙基氨基)乙基]-2-甲基-7-(1,2-二氢-5-
氟-2-氧代-
3H-吲哚-3-基)-4,5,6,7-四氢-1H-
吲哚-3-羧酰胺的酸加盐,其中盐包括至少一种盐,包括
L-苹果酸盐、盐酸盐、
磷酸盐、
L-酒石酸盐、
苯磺酸盐、
硫酸盐、
甲磺酸盐、
琥珀酸盐、
柠檬酸盐、
富马酸盐、
对甲苯磺酸盐、
溴化氢盐、
L-苹果酸盐、
乳酸盐、
乙酸盐或
马来酸盐。还提供了包括这些盐化合物的药物组合物,以及通过给予盐化合物的治疗有效量作为药物制剂的治疗方法。